108 related articles for article (PubMed ID: 16117969)
1. Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test.
De Luca PM; Mayrink W; Santiago MA; Nogueira R; Conceição-Silva F; Mélo G; Mendonça SC
Trans R Soc Trop Med Hyg; 2003; 97(6):709-12. PubMed ID: 16117969
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis.
De Luca PM; Mayrink W; Pinto JA; Coutinho SG; Santiago MA; Toledo VP; Costa CA; Genaro O; Reis AB; Mendonça SC
Acta Trop; 2001 Dec; 80(3):251-60. PubMed ID: 11700183
[TBL] [Abstract][Full Text] [Related]
3. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.
Mahmoodi M; Khamesipour A; Dowlati Y; Rafati S; Momeni AZ; Emamjomeh M; Hejazi H; Modabber F
Clin Exp Immunol; 2003 Nov; 134(2):303-8. PubMed ID: 14616791
[TBL] [Abstract][Full Text] [Related]
4. Dichotomy of protective cellular immune responses to human visceral leishmaniasis.
Khalil EA; Ayed NB; Musa AM; Ibrahim ME; Mukhtar MM; Zijlstra EE; Elhassan IM; Smith PG; Kieny PM; Ghalib HW; Zicker F; Modabber F; Elhassan AM
Clin Exp Immunol; 2005 May; 140(2):349-53. PubMed ID: 15807861
[TBL] [Abstract][Full Text] [Related]
5. Reevaluating leishmanin skin test as a marker for immunity against cutaneous leishmaniasis.
Momeni Boroujeni A; Aminjavaheri M; Moshtaghian B; Momeni A; Momeni AZ
Int J Dermatol; 2013 Jul; 52(7):827-30. PubMed ID: 23621513
[TBL] [Abstract][Full Text] [Related]
6. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia.
Sassi A; Louzir H; Ben Salah A; Mokni M; Ben Osman A; Dellagi K
Clin Exp Immunol; 1999 Apr; 116(1):127-32. PubMed ID: 10209516
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of leishmanin skin test and its relationship with the clinical form and duration of cutaneous leishmaniasis.
Sadeghian G; Momeni A; Siadat AH; Yousefi P
Dermatol Online J; 2006 Dec; 12(7):3. PubMed ID: 17459289
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis.
De Luca PM; Mayrink W; Alves CR; Coutinho SG; Oliveira MP; Bertho AL; Toledo VP; Costa CA; Genaro O; Mendonça SC
Vaccine; 1999 Mar; 17(9-10):1179-85. PubMed ID: 10195630
[TBL] [Abstract][Full Text] [Related]
9. A review of the leishmanin skin test: A neglected test for a neglected disease.
Carstens-Kass J; Paulini K; Lypaczewski P; Matlashewski G
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009531. PubMed ID: 34292942
[TBL] [Abstract][Full Text] [Related]
10. Reappraisal of Leishmanin Skin Test (LST) in the management of American Cutaneous Leishmaniasis: A retrospective analysis from a reference center in Argentina.
Krolewiecki AJ; Almazan MC; Quipildor M; Juarez M; Gil JF; Espinosa M; Canabire M; Cajal SP
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0005980. PubMed ID: 28981507
[TBL] [Abstract][Full Text] [Related]
11. The effect of repeated leishmanin skin testing on the immune responses to Leishmania antigen in healthy volunteers.
Satti I; el Hassan A; Khalil el TA; Akuffo H
Trans R Soc Trop Med Hyg; 2002; 96(5):565-7. PubMed ID: 12474491
[TBL] [Abstract][Full Text] [Related]
12. Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited.
Nylén S; Khamesipour A; Mohammadi A; Jafari-Shakib R; Eidsmo L; Noazin S; Modabber F; Akuffo H
Vaccine; 2006 Nov; 24(47-48):6944-54. PubMed ID: 17049693
[TBL] [Abstract][Full Text] [Related]
13. IFN-γ production to leishmania antigen supplements the leishmania skin test in identifying exposure to L. braziliensis infection.
Schnorr D; Muniz AC; Passos S; Guimaraes LH; Lago EL; Bacellar O; Glesby MJ; Carvalho EM
PLoS Negl Trop Dis; 2012; 6(12):e1947. PubMed ID: 23285304
[TBL] [Abstract][Full Text] [Related]
14. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
15. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.
Vélez ID; Gilchrist K; Arbelaez MP; Rojas CA; Puerta JA; Antunes CM; Zicker F; Modabber F
Trans R Soc Trop Med Hyg; 2005 Aug; 99(8):593-8. PubMed ID: 15893351
[TBL] [Abstract][Full Text] [Related]
16. Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.
Muniz AC; Bacellar O; Lago EL; Carvalho AM; Carneiro PP; Guimarães LH; Rocha PN; Carvalho LP; Glesby M; Carvalho EM
J Infect Dis; 2016 Aug; 214(4):570-6. PubMed ID: 27190181
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of leishmanin skin test in patients of acute cutaneous leishmaniasis.
Manzur A; Bari Au
Dermatol Online J; 2006 May; 12(4):2. PubMed ID: 17083857
[TBL] [Abstract][Full Text] [Related]
18. Response to heterologous leishmanins in cutaneous leishmaniasis in Nigeria--discovery of a new focus.
Agwale SM; Duhlinska DD; Grimaldi Júnior G
Mem Inst Oswaldo Cruz; 1998; 93(1):23-7. PubMed ID: 9698838
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopina M; Hidalgo A; Cevallos W; Correa J
Vaccine; 2004 Mar; 22(9-10):1320-6. PubMed ID: 15003662
[TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of immune responses in leishmaniasis: the use of cross-species leishmanin preparations for skin testing.
Akuffo H; Darce M; Maasho K; Berhan TY
Am J Trop Med Hyg; 1995 Jul; 53(1):16-22. PubMed ID: 7625529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
